AKT1 and breast cancer: SEMA4B‐211aa inhibits the production of PIP3 by competing with p110 for p85 binding, thereby inhibiting the phosphorylation of the Thr308 site of AKT and ultimately negatively regulating the PI3K/AKT signalling pathway, thereby inhibiting breast cancer progression.64